Effect of simvastatin use on bone mineral density in women with type 2 diabetes

Endocrine Practice

Volumn 13, Issue 2, 2007, Pages 114-116

  Uysal, Ali Riza ^a   Delibasi, Tuncay ^a   Erdogan, Murat F ^a   Kamel, Nuri ^a   Baskal, Nilgun ^a   Tonyukuk, Vedia ^a   Corapcioglu, Demet ^a   Güllü, Sevim ^a   Erdogan, Gurbuz ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; SIMVASTATIN;

AGED; ARTICLE; BONE DENSITY; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HIP; HUMAN; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIODENSITOMETRY; SPINE; TIME;

AGED; ANTILIPEMIC AGENTS; BONE DENSITY; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; SIMVASTATIN; SPINE; TIME FACTORS;

EID: 34447320517     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.2.114     Document Type: Article

References (23)

1. Oxlund H, Andreassen TT. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone. 2004;34:609-618.
2. Hatano H, Maruo A, Bolander ME, Sarkar G. Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci. 2003;8:842-848.
3. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
4. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001;280:874-877.
5. Bauer DC, Mundy GR, Jamal SA, et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res. 1999;14:1188.
6. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 2000;355:2218-2219.
7. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-2188.
8. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283:3211-3216.
9. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-3210.
10. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. Statin drugs and the risk of fracture. JAMA. 2000;284:1921-1922.
11. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 2000;85:1137-1142.
12. Kano K, Nishikura K, Yamada Y, Arisaka O. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin Nephrol. 2005;63:74-79.
13. Tikiz C, Tikiz H, Taneli F, Gumuser G, Tuzun C. Effects of simvastatin on bone mineral density and remodeling parameters in postmenopausal osteopenic subjects: 1-year follow-up study. Clin Rheumatol. 2005;24:447-452.
14. Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med. 2000;160:2865.
15. Sirola J, Sirola J, Honkanen R, et al. Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int. 2002;13:537-541.
16. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (Geelong Osteoporosis Study). Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537-540.
17. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001;285:1850-1855.
18. Garret IR, Escobedo A, Esparza J, Mundy GR. Cerivastatin increases BMP-2 expression in vivo and bone formation in concentrations of two orders of magnitude lower than other statins. J Bone Miner Res. 1999;14(Suppl):1189.
19. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000;271:688-692.
20. Grasser WA, Baumann AP, Petras SF, et al. Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact. 2003;3:53-62.
21. Hatzigeorgiou C, Jackson JL. Hydroxymethylglutarylcoenzyme A reductase inhibitors and osteoporosis: a metaanalysis. Osteoporos Int. 2005;16:990-998.
22. Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutarylcoenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980;77:3957-3961.
23. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133-138.